Abstract
A mortality gap between the United States and other high-income nations emerged before the pandemic. International comparisons of Covid-19 mortality suggest this gap might have increased during the pandemic.
Applying average mortality rates of the five largest West European countries to the US population shows that the number of “excess deaths” attributable to this mortality gap continues to increase year after year in the United States. The annual number of such excess deaths has doubled between 2017 and 2021, with most of the increase occurring during the pandemic (+89.1% between 2019 and 2021). In 2021, excess mortality in the United States relative to its European peers contributed 892,491 excess deaths, amounting to 25.8% of all US deaths that year, up from 15.7% in 2017.
Of the 450,224 excess deaths added between 2017 and 2021, 42,317 are attributable to population change (9.4%), 230,672 to differential rates of Covid-19 mortality (51.2%), and the remaining 177,235 to differential rates of mortality from other causes (39.4%, possibly including misclassified deaths due to Covid-19). The contribution of Covid-19 mortality to excess mortality in the United States (relative to its European peers) grew between 2020 and 2021 due to diverging trends in Covid-19 mortality, especially towards the end of 2021 as US vaccination rates plateaued at lower levels than in European countries. While this contribution might be transient, divergent trends in mortality from other causes persistently separates the United States from West European countries. Excess mortality is particularly high between ages 15 and 64. In 2021, nearly half of all US deaths in this age range are excess deaths (48.0%).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Writing update (analyses unchanged)
Data Availability
All materials from other sources are publicly available.
